WASHINGTON (dpa-AFX) - Regeneron Pharmaceuticals, Inc. (REGN) Monday said the U.S. Food and Drug Administration has accepted for priority review the drugmaker's vision-impairment therapy, Eylea, to treat retina damage in diabetics.
Regeneron's supplemental biologics license application is for treating diabetic retinopathy in people with diabetic macular edema.
Eylea is already approved in the U.S. for treating age-related macular degeneration, and macular edema as well as diabetic macular edema.
The target action date under the Prescription Drug User Fee Act is March 30, 2015.
Copyright RTT News/dpa-AFX